BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SuppreMol Initiates Phase Ib/Iia Clinical Trial With Its Lead Candidate SM101


4/14/2010 3:27:34 PM

Martinsried/Munich, Germany, April 12, 2010 -- SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced the initiation of a Phase Ib/IIa clinical trial with its lead product SM101 in Idiopathic Thrombocytopenic Purpura (ITP).

The first patient in the multi-centric, randomized, double-blind, placebo-controlled, dose escalating study has been enrolled in Poland. In the Phase Ib, up to 36 patients will receive repeated doses of SM101 weekly for four weeks, or matching placebo intravenously. Subsequently, SuppreMol plans to enroll an additional 15 patients to expand the study to a Phase IIa parallel-group clinical trial, which will be conducted in Germany, Belgium, Poland, and Russia.

The primary endpoint is safety based on the incidence of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE). The main efficacy endpoint is the proportion of subjects with a substantial platelet response (i.e. more than 30,000 platelets/µl blood). Secondary endpoints comprise number of bleeding events, time to reach platelet response, duration of platelet response, proportion of subjects with rescue medication, and dose reduction of concomitant ITP medication.

In a Phase Ia trial in 48 healthy volunteers started in April 2009 no SM101-associated adverse reactions have been observed. Detailed results of this study will be published soon.

"Following the successful completion of the Phase Ia trial in March this year, we are very pleased to expand our clinical studies with our lead molecule SM101," said Peter Buckel, CEO of SuppreMol. "We are looking forward to completing the Phase Ib/IIa trial by December, 2011, and to generate some initial data on the efficacy of SM101 by February, 2011 from phase Ib then."


Read at BioSpace.com

SuppreMol
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES